Oxford vaccine trial to continue despite volunteer's death
London, Oct 22 (Prensa Latina) The Covid-19 vaccine candidate developed by Oxford University and Anglo-Swedish pharma AstraZeneca will continue its clinical trials in Brazil, despite the death of one of the volunteers, it was reported in London on Thursday.
According to Sky News television, which cited sources from the English university, an independent study of what happened found no reason to be concerned about the safety of the Brazilian trial.
AstraZeneca alleged that the company's policy does not allow to comment on individual events, but assured that in the case of the Brazilian volunteer, all investigation steps were followed. According to the press of that South American country, the volunteer would have received the placebo and not the Covid-19 vaccine.
UK clinical trials were put on hold for two weeks in September after one of the British volunteers developed dangerous side effects.
The Oxford vaccine, as it is now popularly known, is in Phase 3 clinical trial, the last before a vaccine is declared safe for mass vaccination. It is being tested in several countries, among them the United States, Brazil and India, the three hardest-hit countries by the pandemic.
|By the minute||Most read|